In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Boots

This article was originally published in The Rose Sheet

Executive Summary

Novartis Consumer Health appointed Clearasil distributor in U.S. and Canada, effective July 2, to strengthen position of skin care brand, UK firm announces. Former Clearasil marketer Procter & Gamble will distribute brand until July 1 and will continue to manufacture it in North America until further notice, Boots says. Novartis and Boots will work together to evaluate opportunities for Clearasil, including product revamp and possibility of bringing other Boots products in development to U.S., firm says. Boots purchased Clearasil for $340 mil. last fall in effort to gain access to U.S. OTC market (1"The Rose Sheet" Oct. 23, 2000, p. 3)

You may also be interested in...



Boots Healthcare Gains Access To U.S. Market Through Clearasil Buy

Boots Healthcare International views its acquisition of the Clearasil acne prevention and treatment brand as a possible springboard for creating an OTC drug marketing presence in the U.S.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

UsernamePublicRestriction

Register

LL1123738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel